Clinical Trial UCI-16-52 Click to view printable page

Title

A Single Arm, Open-Label, Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib Tablets in Women with Recurrent Platinum Resistant Epithelial Ovarian Cancer, Including Fallopian Tube and/or Primary Peritoneal Cancer who Do Not Carry a Deleterious or Suspected Deleterious Germline BRCA Mutation

Principal Investigator

Krishnansu Tewari

Details

Learn More

For information about cancer clinical trials at the Chao Family Comprehensive Cancer Center, please call toll-free: 877.UC.STUDY (877.827.8839) or email ucstudy@uci.edu

If you would like more information regarding this specific trial, please leave your name, phone number, and email. We will contact you promptly.

Name: Email: Phone: